ReviewBlood transfusion = Trasfusione del sangue2011
Pathophysiology and therapeutic options in primary immune thrombocytopenia.
Review in Blood transfusion = Trasfusione del sangue, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04311593 (Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura
Who cites it
15 citing papers in PubMed.
- In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor.Blood transfusion = Trasfusione del sangue · 2014Trial
- Influence of the Immune Checkpoint Inhibitors on the Hemostatic Potential of Blood Plasma.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025Article
- Article
- Immune thrombocytopenic purpura and legionella infection: A case report highlighting the association.IDCases · 2022Article
- Review
- ESPED survey on newly diagnosed immune thrombocytopenia in childhood: how much treatment do we give?Molecular and cellular pediatrics · 2021Article
- Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach.International journal of molecular sciences · 2021Article
- Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia.Journal of hematology · 2018Article
- Advances in Diagnosis and Treatments for Immune Thrombocytopenia.Clinical medicine insights. Blood disorders · 2016Review
- Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?Vox sanguinis · 2016Review
- Changes in follicular helper T cells in idiopathic thrombocytopenic purpura patients.International journal of biological sciences · 2015Article
- Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag.Platelets · 2014Article
- Pathophysiology and management of primary immune thrombocytopenia.International journal of hematology · 2013Review
- Pulsed high-dose dexamethasone improves interleukin 10 secretion by CD5+ B cells in patients with primary immune thrombocytopenia.Journal of clinical immunology · 2012Article
- Human platelet antigens and primary immune thrombocytopenia.Revista brasileira de hematologia e hemoterapiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.